rt-PA
rt-PA is a pharmaceutical drug with 22 clinical trials. Currently 2 active trials ongoing. Historical success rate of 93.3%.
Success Metrics
Based on 14 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
3
Mid Stage
11
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
87.5%
14 of 16 finished
12.5%
2 ended early
2
trials recruiting
22
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Observational Study to Assess the Safety of rhTNK-tPA (Mingfule®) vs. Rt-PA (Actilyse®) in Treating Acute Ischemic Stroke
Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical Trial
Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
Study on Hibernation-like Therapy Based on Mechanical Thrombectomy
Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients
Clinical Trials (22)
Observational Study to Assess the Safety of rhTNK-tPA (Mingfule®) vs. Rt-PA (Actilyse®) in Treating Acute Ischemic Stroke
Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical Trial
Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
Study on Hibernation-like Therapy Based on Mechanical Thrombectomy
Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients
1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients
rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)
The RAPID - PE Study: RESCUE Advanced Protocol for the Treatment of Pulmonary Embolism
tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
First - In - Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism
Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ
Argatroban Plus R-tPA for Acute Ischemic Stroke
Butyphthalide in Combination With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke
Intravenous Thrombolysis Registry for Chinese Ischemic Stroke Within 4.5 h Onset
Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III
Argatroban Plus r-tPA for Posterior Circulation Infarction(AR-PCI)
Superiority of Rt-PA + Tenecteplase in Comparison With Rt-PA Only in Proximal Middle Cerebral Artery Occlusion
Dose-effect Relationship of Rt-PA on ICH Evacuation
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke
Trial to Compare the Efficacy and Safety of a Single Bolus of TNK-tPA (Tenecteplase, Metalyse®) With Accelerated Infusion of Rt-PA (Alteplase, Actilyse®) in Asian Patients With Acute Myocardial Infarction
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 22